Cholecystokinin (CCK) has been suggested to be both pro-nociceptive and "anti-
opioid" by actions on
pain-modulatory cells within the rostral ventromedial medulla (RVM). One consequence of activation of RVM CCK₂ receptors may be enhanced spinal nociceptive transmission; but how this might occur, especially in states of pathological
pain, is unknown. Here, in vivo microdialysis was used to demonstrate that levels of RVM CCK increased by approximately 2-fold after
ligation of L₅/L₆ spinal nerves (SNL). Microinjection of CCK into the RVM of naïve rats elicited
hypersensitivity to tactile stimulation of the hindpaw. In addition, RVM CCK elicited a time-related increase in (
prostaglandin-E₂) PGE₂ measured in cerebrospinal fluid from the lumbar spinal cord. The peak increase in spinal PGE₂ was approximately 5-fold and was observed at approximately 80 minutes post-RVM CCK, a time coincident with maximal RVM CCK-induced mechanical
hypersensitivity. Spinal administration of
naproxen, a nonselective COX-inhibitor, significantly attenuated RVM CCK-induced hindpaw tactile
hypersensitivity. RVM-CCK also resulted in a 2-fold increase in spinal 5-hydroxyindoleacetic
acid (5-HIAA), a 5-hydoxytryptophan (5-HT) metabolite, as compared with controls, and mechanical
hypersensitivity that was attenuated by spinal application of
ondansetron, a 5-HT₃ antagonist. The present studies suggest that chronic nerve injury can result in activation of descending facilitatory mechanisms that may promote
hyperalgesia via ultimate release of PGE₂ and
5-HT in the spinal cord.